A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: a randomized phase II study to evaluate toxicity and dose intensity

Ken Hirao; Hirofumi Kawamoto; Ichiro Sakakihara; Yasuhiro Noma; Naoki Yamamoto; Ryo Harada; Koichiro Tsutsumi; Masakuni Fujii; Hironari Kato; Naoko Kurihara; Osamu Mizuno; Tsuneyoshi Ogawa; Etsuji Ishida; Kazuhide Yamamoto

首页> 外文期刊>International Journal of Clinical Oncology >A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: a randomized phase II study to evaluate toxicity and dose intensity

【24h】

A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: a randomized phase II study to evaluate toxicity and dose intensity

机译：吉西他滨单药治疗晚期胰腺癌的4周和3周时间表：评估毒性和剂量强度的随机II期研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

This randomized phase II study compared the efficacy and toxicity between 4-week and 3-week schedules of gemcitabine monotherapy in advanced pancreatic cancer.

机译：这项II期随机研究比较了吉西他滨单药治疗4周和3周方案在晚期胰腺癌中的疗效和毒性。

著录项

来源
《International Journal of Clinical Oncology》 |2011年第6期|p.637-645|共9页
作者
Ken Hirao; Hirofumi Kawamoto; Ichiro Sakakihara; Yasuhiro Noma; Naoki Yamamoto; Ryo Harada; Koichiro Tsutsumi; Masakuni Fujii; Hironari Kato; Naoko Kurihara; Osamu Mizuno; Tsuneyoshi Ogawa; Etsuji Ishida; Kazuhide Yamamoto;
展开▼
作者单位

Departments of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama, 700-8558, Japan;

Departments of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama, 700-8558, Japan;

Departments of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama, 700-8558, Japan;

Departments of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama, 700-8558, Japan;

Departments of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama, 700-8558, Ja;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词
Pancreatic cancer; Gemcitabine; Chemotherapy; 4-week schedule; 3-week schedule; Dose intensity;

机译：胰腺癌;吉西他滨;化学疗法;4周时间表;3周时间表;剂量强度;
入库时间 2022-08-18 00:10:35

相似文献

外文文献
中文文献

1. A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: A randomized phase II study to evaluate toxicity and dose intensity [J] . HiraoK., KawamotoH., SakakiharaI., International journal of clinical oncology . 2011,第6期

机译：吉西他滨单药治疗晚期胰腺癌的4周和3周时间表：评估毒性和剂量强度的随机II期研究
2. First line chemotherapy with gemcitabine in advanced non-small cell lung cancer elderly patients: a randomized phase II study of 3-week versus 4-week schedule. [J] . Quoix E, Breton JL, Ducolone A, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2005,第3期

机译：吉西他滨一线化疗治疗晚期非小细胞肺癌老年患者：一项为期3周和4周的II期随机研究。
3. Gemcitabine and cisplatin treatment over a 3-week versus a 4-week dosing schedule: a randomized trial coducted in Chinese patients with nonsmall cell lung cancer [J] . LIAO Mei-lin, ZHU Yun-zhong, LI Long-yun, 中华医学杂志（英文版） . 2008,第010期

机译：吉西他滨和顺铂治疗3周和4周的给药方案：在中国非小细胞肺癌患者中进行的一项随机试验
4. Phase I/II clinical trials on the effect of weekly paclitaxel (wPTX) and wPTX containing combination regimens for advanced and metastatic gastric cancer -ECRIN group studies [C] . Sakamoto J, Kodera Y, Kobayashi M, International Gastric Cancer Congress . 2009

机译：I / II期临床试验关于每周紫杉醇（WPTX）和WPTX含有晚期和转移性胃癌组合方案的临床试验 - 分泌组研究
5. A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer [O] . M. Ueno, T. Okusaka, Y. Omuro, -1

机译：S-1加口服亚叶酸钙与S-1单药治疗吉西他滨难治性晚期胰腺癌的II期随机研究
6. Randomized Phase II Study of Gemcitabine Monotherapy vs. Gemcitabine with an EPA-Enriched Oral Supplement in Advanced Pancreatic Cancer [O] . Makoto Ueno, Kazuya Sugimori, Masataka Taguri, 2021

机译：吉西他滨单疗法对吉西他滨的随机期II研究，富含EPA富含胰腺癌的EPA口腔补充剂

A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: a randomized phase II study to evaluate toxicity and dose intensity

摘要

著录项

相似文献

相关主题

期刊订阅